Equillium Inc
-0.03 (-2.5%)
Upgrade to Real-Time
Regular Market
Volume 22,373
Bid Price 1.17
Ask Price 1.20
News (1)
Day High 1.21


52 Week Range


Day Low 1.1509
Company Name Stock Ticker Symbol Market Type
Equillium Inc EQ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -2.5% 1.17 10:40:09
Open Price Low Price High Price Close Price Prev Close
1.19 1.1509 1.21 1.20
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
87 22,373 $ 1.18 $ 26,298 - 0.790001 - 4.3799
Last Trade Time Type Quantity Stock Price Currency
10:40:09 1 $ 1.185 USD


Draw Mode:

Equillium Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 40.26M 34.41M 17.20M $ - $ - -1.36 -0.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.18M 3.70%

more financials information »

Equillium News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EQ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.001.350.9871.18738,5640.1717.0%
1 Month1.151.350.981.16255,5310.021.74%
3 Months1.691.880.7900011.16130,483-0.52-30.77%
6 Months2.333.200.7900011.92170,384-1.16-49.79%
1 Year4.094.37990.7900012.07102,813-2.92-71.39%
3 Years4.8630.200.79000116.55594,912-3.69-75.93%
5 Years14.3530.200.79000116.33425,059-13.18-91.85%

Equillium Description

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.